Risk factor
High price volatility
Profitability factor
Favourable analyst view
About
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. Specifically, the stock is overpriced on P/FCF.
Target Price
The average target price of IMCR is 64 and suggests 77% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell